OncoSil Medical Ltd (AU:OSL) has released an update.
OncoSil Medical Limited has secured UKCA renewal certificates for its pancreatic cancer treatment device, OncoSil™, without any post-market restrictions, enhancing its operational efficiency in the UK. This regulatory milestone underscores the device’s safety and promises to streamline regulatory processes and reduce costs. The company anticipates further growth as it expects upcoming MDR approval, potentially broadening its market presence across Europe.
For further insights into AU:OSL stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
